Cargando…

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study

BACKGROUND/OBJECTIVE: This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late disease (LD). METHODS: The phase 3, double-blind, GO-ALIVE study randomized patients to IV golimumab 2 mg/kg at weeks 0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deodhar, Atul A., Shiff, Natalie J., Gong, Cinty, Hsia, Elizabeth C., Lo, Kim Hung, Kim, Lilliane, Xu, Stephen, Reveille, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336574/ https://www.ncbi.nlm.nih.gov/pubmed/35653615 http://dx.doi.org/10.1097/RHU.0000000000001853

Ejemplares similares

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2023)

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2022)

Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials
por: Gensler, L. S., et al.
Publicado: (2020)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
por: Braun, Jürgen, et al.
Publicado: (2014)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
por: Inman, Robert D., et al.
Publicado: (2016)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
por: Borse, Rebekah H., et al.
Publicado: (2017)

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
por: Heslinga, SC, et al.
Publicado: (2018)

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty‐Four of the GO‐VIBRANT Study
por: Kavanaugh, Arthur, et al.
Publicado: (2017)

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab
por: Lee, Jeong Seok, et al.
Publicado: (2018)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Erythema nodosum after golimumab treatment in ankylosing spondylitis patients: a case report and literature review
por: Kudsi, Maysoun, et al.
Publicado: (2023)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial
por: Ogdie, Alexis, et al.
Publicado: (2021)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
por: Tesser, John, et al.
Publicado: (2022)

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

ANKH variants associated with ankylosing spondylitis: gender differences
por: Tsui, Hing Wo, et al.
Publicado: (2005)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Geographic Variations in Diagnosis and Treatment of Ankylosing Spondylitis in the United States: A Real-World Study
por: Deodhar, Atul, et al.
Publicado: (2021)

Persistence, Discontinuation, and Switching Patterns of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients in the United States
por: Hunter, Theresa, et al.
Publicado: (2019)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
por: Broadwell, Aaron, et al.
Publicado: (2023)

Ankylosing Spondylitis in Iran; Late Diagnosis and Its Causes
por: Hajialilo, Mehrzad, et al.
Publicado: (2014)

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
por: Bingham, Clifton O., et al.
Publicado: (2023)

IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
por: Baeten, Dominique, et al.
Publicado: (2021)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort
por: Rahbar, Mohammad H., et al.
Publicado: (2018)

Bath Ankylosing Spondylitis Disease Activity Index is Associated With the Quality of Sleep in Ankylosing Spondylitis Patients
por: Song, Byung Wook, et al.
Publicado: (2021)

Medical Treatment of Ankylosing Spondylitis
por: Moon, Kyoung-Ho, et al.
Publicado: (2014)

Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
por: Mundwiler, Matthew L, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_cp2rpv9i32nnqj0pe9sc22ei3i